About Early Signs
Standard lab reference ranges are designed to flag disease — not optimize health. Early Signs bridges this gap by tracking your biomarkers against ranges used by the world's leading longevity researchers and health optimization experts.
Our Mission
Getting a bloodwork panel back and being told everything is “normal” while feeling suboptimal is a frustratingly common experience. Standard lab reference ranges exist to identify clinical disease — they're population averages that tell you whether you're sick compared to everyone else who got tested. They were never designed to tell you whether you're optimized.
There is a meaningful gap between “normal” and “optimal.” A Vitamin D level of 32 ng/mL might fall inside the standard reference range, but the longevity research community consistently targets 50–70 ng/mL for immune function, cancer risk reduction, and mood. An LDL of 110 mg/dL might not trigger a call from your doctor, but Peter Attia argues that ApoB is the more relevant marker — and that an ApoB under 60 mg/dL is the real longevity target. That gap between what your lab flags as fine and what the best researchers consider optimal is what Early Signs was built to surface.
We believe everyone should have access to the same biomarker intelligence that longevity-focused physicians use with their patients. Not just “are you sick?” — but “are you optimized?” Early Signs makes it easy to upload, track, and understand your bloodwork against evidence-based optimal ranges, without needing a concierge medicine practice.
How Our Ranges Are Sourced
Every optimal range in Early Signs is derived from publicly available research, published protocols, clinical guidelines, and content from recognized longevity researchers. Our process for each biomarker is:
- 1.Identify the standard clinical reference range from major labs (Quest, LabCorp).
- 2.Review peer-reviewed literature for longevity-specific targets — observational studies, RCTs, and meta-analyses.
- 3.Cross-reference the protocols and stated targets of recognized longevity researchers (see below).
- 4.Set an optimal range reflecting the scientific consensus for longevity optimization, not just disease avoidance.
- 5.Document the rationale for each marker's range, noting where expert opinion diverges.
Important: Early Signs does not provide medical advice. Optimal ranges are reference points for discussion with your physician, not prescriptive targets. Individual variation, genetics, medications, and health conditions all affect what is right for you specifically. Always consult a qualified physician before making changes to your health regimen.
Our Data Principles
We never sell your health data
Your biomarker data is yours. We do not sell it, license it, or share it with advertisers, data brokers, or third parties — ever.
Separation of identity and health data
Your personal information (name, email) and health data (lab results) are stored in separate database layers, limiting exposure in any security event.
Encryption at rest and in transit
All data is encrypted with AES-256 at rest and TLS 1.3 in transit. We use SOC 2 compliant infrastructure.
Full data portability and deletion
Export all your data or request permanent deletion at any time from Settings. Deletion requests are honored within 30 days.
MHMDA and CCPA compliance
We record explicit consent for health data collection at signup and honor all applicable rights — access, export, correction, and deletion.
Expert Sources
Our research references publicly available content from the following researchers and health optimization experts. Early Signs has no affiliation with, and has not been reviewed or endorsed by, any of the individuals listed below. All ranges are derived from publicly available sources.
Dr. Peter Attia
Longevity medicine, cardiovascular risk, metabolic health
His framework for ApoB, Lp(a), insulin resistance, and metabolic health directly informs our lipid and metabolic marker ranges.
Dr. Andrew Huberman
Neuroscience, hormones, sleep, supplements
His work on testosterone, cortisol, sleep quality, and neuromodulators grounds our hormonal and neurological marker thresholds.
Dr. Rhonda Patrick
Nutrition, genetics, inflammation, micronutrients
Her research on Vitamin D, omega-3s, magnesium, and inflammatory markers shapes our supplementation and deficiency thresholds.
Dr. Mark Hyman
Functional medicine, metabolic health, nutrition
His functional medicine approach to reading labs beyond standard ranges informs how we contextualize insulin, ferritin, and homocysteine.
Bryan Johnson
Blueprint protocol, aggressive biomarker optimization
His publicly published Blueprint protocol and target values give us real-world aggressive optimization benchmarks for comparison.
Dave Asprey
Biohacking, mitochondrial health, detoxification
His work on mitochondrial health markers and detox pathways contributes context to liver enzyme and oxidative stress markers.
Dr. David Sinclair
Aging biology, NAD+, sirtuins, epigenetic age
His research on aging biomarkers, NAD+ metabolism, and metabolic health informs our longevity-specific interpretations.
Tim Ferriss
Self-experimentation, supplements, health optimization
His systematic self-experimentation provides real-world context on how labs change in response to lifestyle interventions.
Dr. Gabrielle Lyon
Muscle-centric medicine, protein, metabolic health
Her work on muscle mass, protein metabolism, and longevity informs our hormonal and muscle health marker interpretations.
Dr. Casey Means
Metabolic health, CGM, insulin signaling
Her research on metabolic dysfunction and early insulin resistance shapes our glucose, insulin, and HbA1c optimal ranges.
Dr. Andy Galpin
Exercise physiology, performance, recovery
His work on CBC, hematocrit, iron, and performance markers provides context for exercise-focused biomarker interpretation.
Gary Brecka
Gene-based nutrition, methylation, functional health
His work on methylation pathways and homocysteine metabolism informs our B-vitamin and homocysteine optimal thresholds.
Our Editorial Team
Early Signs content is researched and written by our in-house research team, with every article grounded in peer-reviewed literature and the published protocols of the experts listed above.
Meet the research teamQuestions or feedback? support@earlysigns.ai